Introduction
============

Yawning, as a common physiological event, occurs at low frequency in humans and animals (Walusinski, 2009[@B25]). It is a brain-mediated physiological phenomenon in which a variety of neurotransmitters and neuropeptides including dopamine, excitatory amino acids, serotonin, nitric oxide, noradrenaline, -aminobutyric acid (GABA), adrenocorticotropic hormone-related peptides, prolactin, urotensin, oxytocine and opioid peptides are involved (Collins and Eguibar, 2010[@B5]). Additional evidence suggests that brain histamine may also be involved in the induction of yawning (Tamaddonfard et al, 2008a[@B23]).

*Crocus sativus*L.*,*commonly known as saffron, is used in folk medicine as an antispasmodic, nerve sedative, expectorant, eupeptic, anticatarrhal, carminative, diaphoteric, stomachic, aphrodisiac and emmenagogue agent (Schmidt et al., 2007[@B16]). Crocin and safranal are the major biologically active components of saffron (Rios et al., 1996[@B13]). Pharmacological studies have demonstrated antiepileptic, anti-oxidative, anti-inflammatory, neuroprotective, memory improvement and anti-diabetic effects for crocin and safranal (Assimopolou et al., 2005[@B2]; Nam et al., 2010[@B11]; Gadrdoost et al., 2011[@B8]; Boskabady et al., 2012[@B3]; Tamaddonfard et al., 2012a[@B21]; Tamaddonfard et al., 2013a[@B17], b[@B18], c[@B19]).

Regarding the documents showing that crocin and safranal can influence histamine functions (Boskabady et al., 2012[@B3]; Tamaddonfard et al., 2012b[@B22]; Boskabady et al., 2011[@B4]), the present study was designed to investigate the effects of intraperitoneal (i.p.) injection of crocin and safranal on the yawning induced by intracerebroventricular (i.c.v.) administration of histamine. We also examined yawning response of crocin and safranal after blocking histamine function with mepyramine, a histamine H~1~ receptor antagonist.

Materials and Methods
=====================

**Animals**

Healthy adult male Wistar rats, weighing 250--280 g, were used in this study. Rats were kept in polyethylene cages with food and water available *ad libitum* in a laboratory with controlled ambient temperature (22 ± 0.5°C) and under a 12hr-12hr light-dark cycle (lights on 07:00). Experiments were carried out between 13:00 and 16:00. The experiment protocol was approved by the Laboratory Animal Care and Use Center of the Faculty of Veterinary Medicine of Urmia University, Urmia, Iran.

**Chemicals**

Chemicals used in this study included crocin (Fluka, Germany), safranal, (Sigma-Aldrich, USA), histamine dihydrochloride (Merck, Darmstadt, Germany) and mepyramine maleate (Sigma-Aldrich, USA). Crocin, histamine and mepyramine were dissolved in normal saline. Safranal was dissolved in liquid paraffin (Amin and Hosseinzadeh, 2012[@B1]; Tamaddonfard et al., 2013c[@B19]).

**Treatment groups**

Forty eight rats were used in our experiments. Six rats were injected (i.c.v.) with normal saline and histamine (5, 10 and 20 µg/rat). Six were injected with mepyramine (40 µg/rat, i.c.v.) and mepyramine (40 µg/rat) plus histamine (20 µg/rat). Six rats were treated with normal saline and crocin (7.5, 15 and 30 mg/kg, i.p.). Six rats were injected (i.c.v.) of histamine at a dose of 10 µg/rat after injection of crocin (30 mg/kg, i.p.). Six rats were injected with paraffin and safranal (0.25, 0.5 and 1 mg/kg, i.p.). Six rats were injected with histamine (10 µg/rat, i.c.v.) after injection of safranal (1 mg/kg, i.p.). To six rats, crocin (30 mg/kg, i.p.) was injected before injection of mepyramine (40 µg/rat, i.c.v.) plus histamine (20 µg/rat, i.c.v.). Safranal at a dose of 1 mg/kg (i.p.) was injected before injection of mepyramine (40 µg/rat, i.c.v.) plus histamine (20 µg/rat, i.c.v.) to six rats. Four-day- elapsed time was considered among injections. Crocin and safranal were injected (i.p.) 20 and 30 min and mepyramine was injected (i.c.v) 5 min before injection (i.c.v.) of histamine.

**Surgery**

After a 15-day adaptation period, each rat was anesthetized with injection (i.p.) of a mixture of ketamine (100 mg/kg) and xylazine (10 mg/kg) and then, placed in a stereotaxic apparatus (Stoelting, Wood Lane, IL, USA). The scalp was incised, and the bregma was exposed. A 23-gauge, 12-mm stainless-steel guide cannula was inserted in the right lateral ventricle of the brain. The tip of the cannula was aimed at the following coordinates: 0.8 mm posterior to the bregma, 2 mm lateral to the midline and 4 mm below the top of the skull (Paxinos and Watson, 1997; Tamaddonfard et al., 2008b). The cannula was then fixed to the skull using three screws and dental acrylic. A 12-mm stylet was inserted into the cannula to keep it patent prior to injection. Animals were allowed a 10-day- recovery period before experiments were initiated.

**Drug injection**

For i.c.v. injections of histamine and mepyramin, a 28-gauge 12.5-mm injection needle was attached to a 30 cm polyethylene tube fitted to a 5 µl Hamilton syringe. The volume of the chemical solutions to be injected into the lateral ventricle was 2 µl and the injection was done over a period of 60 sec. Normal saline, paraffin, crocin and safranal were injected (i.p.) using a 25-gauge injection needle at a volume of 1 ml/kg.

**Yawning**

Yawning behavior was defined as a prolonged (more than 1 sec) wide opening of the mouth followed by a rapid closure (Collins, 2005). On the day of testing, rats were placed in clear plastic chambers (30 × 25 × 25 cm) and allowed to habituate to the chamber for a period of 30 min. Injections (i.p. and i.c.v.) were performed at the end of the habituation period, and the number of yawns was counted for a period of 45 min by blinded observers.

**Cannula placement verification**

During the surgery and before i.c.v. injections, a rise in the cerebrospinal fluid through the cannula was observed. For additional confirmation of the placement of the cannula in the lateral ventricle of the brain, at the end of experiments the rats were injected with 2 µl methylene blue (i.c.v.), deeply anesthetized with a high dose of ether and decapitated. The brains were removed and placed in formaldehyde (10%) solution.

After 24 hr, the brains were sliced into 1 mm slices and the placement of the tip of the cannula and distribution of the dye in the lateral ventricle were visually controlled. Data from four rats with an incorrect placement of the cannula were excluded from the analysis.

**Statistical analysis**

The data were analyzed using Graph Pad Prism software version 5. Data were analyzed using one-way analysis of variance (ANOVA) and Tukey\'s tests. All values are expressed as mean ± SEM. Statistical significance was set at p\<0.05.

Results
=======

As shown in [Figures 1](#F1){ref-type="fig"}, 2[@B2] and [3](#F3){ref-type="fig"}, no significant differences were observed in the number of yawns obtained following i.c.v. injection of normal saline (1.2 ± 0.5) and i.p. injection of normal saline (1 ± 0.4) and paraffin (0.8 ± 0.5).

The number of yawns obtained after i.c.v. injection of normal saline was 1.2 ± 0.5. Also, i.c.v. injection of histamine at a dose of 5 µg/rat produced no significant yawning (3.7 ± 1.1), whereas at doses of 10 µg/rat (8.5 ± 1.3) and 20 µg/rat (12.7 ± 1.1) histamine produced significant yawning as compared to normal saline. Mepyramine (40µg/rat, i.c.v.) alone produced no significant yawning in comparison with i.c.v. injection of normal saline, whereas pretreatment with mepyramine (40 µg/rat) before histamine (20 µg/rat) significantly (p\<0.05) prevented histamine-induced yawning ([Figure 1](#F1){ref-type="fig"}).

The number of yawns obtained after i.p. injection of normal saline and crocin at doses of 7.5, 15 and 30 mg/kg were 1 ± 0.4, 1.2 ± 0.7, 1.5 ± 0.7 and 1.8 ± 0.8, respectively ([Figure 2](#F2){ref-type="fig"}). No significant differences were observed among normal saline and crocin treated rats. Prior i.p. injection of crocin at a dose of 30 mg/kg significantly (p\<0.05) increased the number of yawns induced by i.c.v. injection of histamine 10 µg/rat ([Figure 2](#F2){ref-type="fig"}).

![Yawning response after intracerebroventricular (i.c.v.) injection of normal saline, histamine, mepyramine and mepyramine before histamine. Values are expressed as mean ± SEM (n = 6). \* indicates a significant difference (p\<0.05) as compared to normal saline. ^†^ indicates a significant difference (p\<0.05) as compared to histamine (20 µg](AJP-6-442-g001){#F1}

![Yawning response after intraperitoneal (i.p.) injection of normal saline and crocin and intracerebroventricular (i.c.v.) injection of histamine and i.p. injection of crocin before i.c.v injection of histamine. \* indicates a significant difference (p\<0.05) as compared to normal saline.^†^ indicates a significant difference (p\<0.05) as compared to histamine (10 µg](AJP-6-442-g002){#F2}

The number of yawns obtained after i.p. injection of paraffin and safranal at doses of 0.25, 0.5 and 1 mg/kg were 0.8 ± 0.5, 1.5 ± 0.7, 1.7 ± 0.8 and 2.2 ± 1, respectively ([Figure 2](#F2){ref-type="fig"}). No significant differences were observed among paraffin and safranal treated rats. Prior i.p. injection of safranal at a dose of 1 mg/kg significantly (p\<0.05) increased the number of yawns induced by i.c.v. injection of 10 µg/rat of histamine ([Figure 3](#F3){ref-type="fig"}).

![Yawning response after intraperitoneal (i.p.) injection of paraffin and safranal and intracerebroventricular (i.c.v.) injection of histamine and i.p. injection of safranal before i.c.v injection of histamine. \* indicates a significant difference (p\<0.05) as compared to normal saline. † indicates a significant difference (p\<0.05) as compared to histamine (10 µg).](AJP-6-442-g003){#F3}

We observed that i.p. injection of crocin at a dose of 30 mg/kg before i.c.v. injection of mepyramine (40 µg/kg) plus histamine (20 µg/kg) produced yawning ([Figure 4](#F4){ref-type="fig"}). The same result was obtained when safranal (1 mg/kg, i.p.) was injected before i.c.v. injection of 40 µg/kg mepyramine plus 20 µg/kg histamine ([Figure 4](#F4){ref-type="fig"}).

![Yawning response after intraperitoneal (i.p.) injection of crocin and safranal before intracerebroventricular (i.c.v.) injection of mepyramine plus histamine. Values are expressed as means ± SEM (n = 6). ‡ indicates a significant difference (p\<0.05) as compared to mepyramine plus histamine](AJP-6-442-g004){#F4}

Discussion
==========

The results of the present study showed that o.k. injection of histamine produced yawning, which was prevented by mepyramine pretreatment. This means that brain histamine through its H~1~ receptor is involved in yawning modulation. It has been reported that i.c.v. injection of chlorpheniramine (a histamine H~1~ receptor antagonist) and ranitidine (a histamine H~2~ receptor antagonist) inhibited yawning induced by central administration of histamine (Tamaddonfard et al., 2008a[@B23]). It was found that microinjection of histamine into the paraventricular nucleus (PVN) of the brain produces yawning-like response in the pentobarbital sodium-anesthetized rats. In addition, Seki et al. (2002)[@B15] reported the involvement of histamine H~1~ receptor in histamine-induced yawning. In this context, Seki et al. (2003)[@B14] reported a suppressive effect for pirylamine (mepyramine) on the light-induced yawning response in rats.

Our results showed no yawning producing effect for crocin and safranal used alone. There are no reports showing the induction of yawning by these compounds. Natural substances such as curcumin also did not produce yawning when used alone (Tamaddonfard, 2013d[@B20]).

The results of our study showed that crocin and safranal increased the number of yawning induced by histamine. In addition, after blocking the yawning producing effect of histamine by mepyramine, crocin and safranal produced yawning. These indicate that crocin and safranal may affect yawning by activation of histamine receptors. Histamine, through its H~1~, H~2~, H~3~ and H~4~ receptors, mediates many functions including allergy, acid secretion, memory and learning, pain and feeding behavior (Haas et al., 2008[@B9]). It seems that histamine H~1~ and H~2~ receptors are involved in yawning modulation of crocin and safranal. It was found that i.c.v. injection of cimetidine antagonized (+/-) N-n-propylnorapomorphine-induced stretching and yawning in rats (Ferrari and Baggio, 1985[@B7]). Moreover, histamine H~1~ and H~2~ receptor antagonists, chlorpheniramine and ranitidine, respectively, inhibited central histamine-induced yawning (Tamaddonfard et al., 2008a[@B23]). In the peripheral tissues, both crocin and safranal influence histamine H~1~ receptor function. Also, i.p. injection of crocin suppressed histamine-induced local inflammation and increased the anti-inflammatory effect of chlorpheniramine (Tamaddonfard et al., 2012[@B21]). Moreover, the inhibitory effect of safranal and chlorpheniramine on the smooth muscle contraction induced by histamine in trachea chains was reported (Boskabady et al., 2011[@B4]). However, the role of other yawning-promoting mechanisms such as dopamine and acetylcholine systems needs to be considered in the effects of crocin and safranal on yawning. In this context, other active constituents in medicinal plants, such as curcumin of turmeric, used of multiple mechanisms in modulation of yawning (Tamaddonfard, 2013d[@B20]).

In conclusion, the results of the present study indicated that central histaminergic system produced yawning, and mepyramine, a H~1~receptor antagonist, blocked histamine-induced yawning. Crocin and safranal increased the yawning induced by histamine. Also, when histamine action was blocked by mepyramine, crocin and safranal produced yawning.
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